Table 2 Significantly altered canonical pathways, molecular and cellular functions, and predicted upstream regulators associated with DEGs in ALPPS, PVL and PH at 24 h and 96 h.
ALPPS at 24 hr | ALPPS at 96 hr | ||||
|---|---|---|---|---|---|
Canonical Pathways | p-value | Overlap | Canonical Pathways | p-value | Overlap |
Cell Cycle Control of Chromosomal Replication | 1.51E-14 | 51.9% 14/27 | LPS/IL-1 Mediated Inhibition of RXR Function | 8.00E-06 | 9.5% 21/221 |
Mitotic Roles of Polo-Like Kinase | 1.07E-14 | 30.3% 20/66 | Mitotic Roles of Polo-Like Kinase | 6.53E-06 | 16.7% 11/66 |
Role of BRCA1 in DNA Damage Response | 3.84E-12 | 24.4% 19/78 | FXR/RXR Activation | 1.10E-05 | 11.9% 15/126 |
Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 1.37E-12 | 32.7% 16/49 | Hepatic Fibrosis / Hepatic Stellate Cell Activation | 2.47E-04 | 8.7% 16/183 |
Upstream Regulators | p-value | Predicted Activation | Upstream Regulators | p-value | Predicted Activation |
E2F1 | 4.93E-41 | Activated | ERBB2 | 4.36E-22 | Activated |
CCND1 | 2.35E-40 | Activated | TGFB1 | 5.96E-22 | Activated |
RABL6 | 6.32E-38 | Activated | VEGF | 8.37E-21 | Activated |
CDKN1A | 2.73E-57 | Inhibited | CSF2 | 7.02E-16 | Activated |
TP53 | 6.98E-53 | Inhibited | CDKN1A | 3.22E-24 | Inhibited |
Molecular and Cellular Functions | p-value range | # Molecules | Molecular and Cellular Functions | p-value range | # Molecules |
Cell Cycle | 2.22E-05 - 5.88E-29 | 209 | Cell Death and Survival | 4.43E-04 - 4.11E-16 | 257 |
Cellular Assembly and Organization | 2.88E-05 - 6.87E-26 | 186 | Cell Cycle | 4.19E-04 - 4.78E-15 | 135 |
DNA Replication, Recombination, and Repair | 2.22E-05 - 6.87E-26 | 173 | Cellular Assembly and Organization | 4.64E-04 - 4.78E-15 | 176 |
Cell Death and Survival | 2.88E-05 - 1.12E-18 | 278 | DNA Replication, Recombination, and Repair | 4.19E-04 - 4.78E-15 | 107 |
Cell Morphology | 2.88E-05 - 4.40E-15 | 145 | Cellular Growth and Proliferation | 4.61E-04 - 3.22E-15 | 287 |
Physiological System Development and Function | p-value range | # Molecules | Physiological System Development and Function | p-value range | # Molecules |
Organismal Development | 1.15E-06 - 4.56E-09 | 19 | Cardiovascular System Development and Function | 2.79E-04 - 5.36E-09 | 119 |
Connective Tissue Development and Function | 1.74E-05 - 1.02E-10 | 92 | Tissue Development | 3.41E-04 - 6.93E-09 | 211 |
Tissue Development | 2.30E-05 - 5.37E-10 | 106 | Immune Cell Trafficking | 2.77E-04 - 1.04E-08 | 85 |
Tissue Morphology | 2.22E-05 - 4.56E-09 | 30 | Hematological System Development and Function | 2.77E-04 - 3.13E-08 | 112 |
Embryonic Development | 1.15E-06 - 4.56E-09 | 19 | Organismal Development | 3.38E-04 - 9.93E-08 | 128 |
Tox Lists | p-value | Overlap | Tox Lists | p-value | Overlap |
Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 3.86E-12 | 30.8% 16/52 | Renal Necrosis/Cell Death | 2.36E-07 | 7.7% 40/519 |
Liver Proliferation | 4.84E-06 | 9.6% 22/228 | LPS/IL-1 Mediated Inhibition of RXR Function | 1.49E-07 | 10.3% 26/253 |
Aryl Hydrocarbon Receptor Signaling | 9.04E-07 | 11.9% 19/159 | FXR/RXR Activation | 1.10E-05 | 11.9% 15/126 |
CAR/RXR Activation | 2.58E-06 | 27.6% 8/29 | Cardiac Hypertrophy | 1.39E-06 | 7.8% 34/435 |
PVL at 24 hr | PVL at 96 hr | ||||
Canonical Pathways | p-value | Overlap | Canonical Pathways | p-value | Overlap |
Cell Cycle Control of Chromosomal Replication | 3.16E-16 | 51.9% 14/27 | GADD45 Signaling | 9.30E-04 | 15.8% 3/19 |
Mitotic Roles of Polo-Like Kinase | 9.19E-16 | 28.8% 19/66 | Purine Ribonucleosides Degradation to Ribose-1-phosphate | 2.85E-03 | 25.0% 2/8 |
Role of BRCA1 in DNA Damage Response | 3.60E-13 | 23.1% 18/78 | GDP-glucose Biosynthesis | 3.64E-03 | 22.2% 2/9 |
Estrogen-mediated S-phase Entry | 2.95E-12 | 45.8% 11/24 | Glucose and Glucose-1-phosphate Degradation | 4.52E-03 | 20.0% 2/10 |
Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 3.67E-13 | 30.6% 15/49 | Mitotic Roles of Polo-Like Kinase | 4.83E-03 | 6.1% 4/66 |
Upstream Regulators | p-value | Predicted Activation | Upstream Regulators | p-value | Predicted Activation |
E2F1 | 6.82E-48 | Activated | TGFB1 | 7.66E-11 | Activated |
RABL6 | 1.67E-42 | Activated | CSF2 | 1.20E-07 | Activated |
CCND1 | 2.68E-41 | Activated | IL4 | 3.51E-06 | Activated |
CDKN1A | 9.47E-67 | Inhibited | SMARCA4 | 5.42E-06 | Activated |
TP53 | 1.14E-63 | Inhibited | MYCN | 8.83E-04 | Inhibited |
Molecular and Cellular Functions | p-value range | # Molecules | Molecular and Cellular Functions | p-value range | # Molecules |
Cell Cycle | 1.57E-05 - 4.47E-38 | 202 | Cell Death and Survival | 9.04E-03 - 1.69E-09 | 96 |
Cellular Assembly and Organization | 1.48E-05 - 3.39E-34 | 163 | Cellular Growth and Proliferation | 8.25E-03 - 3.76E-09 | 106 |
DNA Replication, Recombination, and Repair | 1.43E-05 - 3.39E-34 | 160 | Cellular Assembly and Organization | 8.66E-03 - 3.93E-07 | 62 |
Cell Death and Survival | 1.47E-05 - 5.70E-21 | 224 | Cell Morphology | 9.04E-03 - 7.52E-07 | 67 |
Cell Morphology | 1.44E-05 - 5.49E-17 | 107 | Cell-To-Cell Signaling and Interaction | 8.89E-03 - 1.32E-06 | 44 |
Physiological System Development and Function | p-value range | # Molecules | Physiological System Development and Function | p-value range | # Molecules |
Reproductive System Development and Function | 1.43E-05 - 9.48E-12 | 52 | Tissue Development | 8.89E-03 - 3.93E-07 | 92 |
Organismal Development | 6.34E-09 - 4.28E-11 | 19 | Lymphoid Tissue Structure and Development | 8.18E-03 - 4.34E-06 | 35 |
Connective Tissue Development and Function | 1.07E-05 - 8.94E-11 | 81 | Organ Morphology | 8.89E-03 - 4.34E-06 | 38 |
Tissue Morphology | 5.72E-06 - 4.28E-11 | 50 | Cardiovascular System Development and Function | 7.67E-03 - 1.32E-06 | 47 |
Embryonic Development | 1.14E-05 - 4.28E-11 | 34 | Tissue Morphology | 8.46E-03 - 4.34E-06 | 65 |
Tox Lists | p-value | Overlap | Tox Lists | p-value | Overlap |
Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 9.76E-13 | 28.8% 15/52 | Nongenotoxic Hepatocarcinogenicity Biomarker Panel | 6.98E-05 | 18.2% 4/22 |
Increases Liver Hyperplasia/Hyperproliferation | 1.29E-06 | 12.6% 13/103 | Recovery from Ischemic Acute Renal Failure (Rat) | 3.63E-04 | 21.4% 3/14 |
Aryl Hydrocarbon Receptor Signaling | 6.67E-08 | 11.3% 18/159 | Cardiac Hypertrophy | 6.20E-04 | 3.0% 13/435 |
Cell Cycle: G1/S Checkpoint Regulation | 5.04E-07 | 16.7% 11/66 | Increases Renal Damage | 1.52E-03 | 6.2% 5/81 |
PH at 24 hr | PH at 96 hr | ||||
Canonical Pathways | p-value | Overlap | Canonical Pathways | p-value | Overlap |
Cell Cycle Control of Chromosomal Replication | 2.21E-15 | 63.0% 17/27 | Production of Nitric Oxide and Reactive Oxygen Species in Macrophages | 5.40E-09 | 10.4% 20/193 |
Role of BRCA1 in DNA Damage Response | 2.90E-12 | 30.8% 24/78 | LXR/RXR Activation | 5.62E-09 | 13.2% 16/121 |
Mitotic Roles of Polo-Like Kinase | 3.83E-12 | 33.3% 22/66 | Acute Phase Response Signaling | 1.18E-07 | 10.1% 17/169 |
Hereditary Breast Cancer Signaling | 4.47E-11 | 21.8% 31/142 | Phagosome Formation | 1.08E-05 | 9.8% 12/122 |
Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 5.42E-11 | 36.7% 18/49 | Fc Receptor-mediated Phagocytosis in Macrophages and Monocytes | 2.70E-05 | 10.8% 10/93 |
Upstream Regulators | p-value | Predicted Activation | Upstream Regulators | p-value | Predicted Activation |
CCND1 | 4.01E-37 | Activated | TNF | 4.33E-30 | Activated |
E2F1 | 5.13E-34 | Activated | IFNG | 2.25E-22 | Activated |
RABL6 | 1.42E-33 | Activated | TP53 | 1.60E-21 | Activated |
CDKN1A | 2.64E-47 | Inhibited | IL6 | 6.78E-20 | Activated |
TP53 | 7.48E-47 | Inhibited | IL1B | 4.93E-19 | Activated |
Molecular and Cellular Functions | p-value range | # Molecules | Molecular and Cellular Functions | p-value range | # Molecules |
Cell Cycle | 6.16E-05 - 1.88E-28 | 281 | Cellular Movement | 8.64E-06 - 1.06E-28 | 161 |
Cellular Assembly and Organization | 6.85E-05 - 1.88E-28 | 163 | Cellular Growth and Proliferation | 1.01E-05 - 2.44E-24 | 228 |
DNA Replication, Recombination, and Repair | 6.85E-05 - 1.88E-28 | 243 | Cell Death and Survival | 9.36E-06 - 3.12E-23 | 201 |
Cell Death and Survival | 7.54E-05 - 6.73E-17 | 420 | Cell-To-Cell Signaling and Interaction | 7.47E-06 - 4.76E-20 | 133 |
Cell Morphology | 1.58E-05 - 4.68E-15 | 229 | Cellular Function and Maintenance | 6.05E-06 - 4.83E-17 | 187 |
Physiological System Development and Function | p-value range | # Molecules | Physiological System Development and Function | p-value range | # Molecules |
Organismal Survival | 1.95E-06 - 3.67E-09 | 292 | Hematological System Development and Function | 9.36E-06 - 1.66E-27 | 177 |
Reproductive System Development and Function | 3.04E-05 - 3.16E-10 | 27 | Immune Cell Trafficking | 8.64E-06 - 4.34E-28 | 120 |
Connective Tissue Development and Function | 5.16E-05 - 8.45E-11 | 132 | Cardiovascular System Development and Function | 9.16E-06 - 2.79E-19 | 120 |
Tissue Development | 6.77E-05 - 8.45E-11 | 117 | Organismal Development | 7.85E-06 - 5.64E-17 | 154 |
Embryonic Development | 7.74E-06 - 3.42E-07 | 27 | Tissue Morphology | 9.16E-06 - 8.60E-20 | 158 |
Tox Lists | p-value | Overlap | Tox Lists | p-value | Overlap |
Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 1.71E-10 | 34.6% 18/52 | Positive Acute Phase Response Proteins | 3.28E-10 | 33.3% 10/30 |
LPS/IL-1 Mediated Inhibition of RXR Function | 2.44E-09 | 15.8% 40/253 | LXR/RXR Activation | 7.16E-09 | 13.0% 16/123 |
Fatty Acid Metabolism | 5.33E-09 | 21.4% 25/117 | Cardiac Necrosis/Cell Death | 1.60E-06 | 7.3% 20/273 |
Aryl Hydrocarbon Receptor Signaling | 1.51E-08 | 18.2% 29/159 | Cardiac Hypertrophy | 6.76E-07 | 6.2% 27/435 |
Xenobiotic Metabolism Signaling | 2.97E-06 | 11.9% 42/352 | Acute Renal Failure Panel (Rat) | 5.80E-06 | 14.5% 9/62 |
